
|Videos|September 26, 2017
Improving Outcomes in Pancreatic Cancer With Perioperative mFOLFIRINOX
Author(s)Davendra Sohal, MD, MPH
Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the need for an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
3
How the Immune System Drives Nerve Growth in TNBC
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5



































